JPS62111925A - Analgesic and sedative in emergence recovery from anesthesia - Google Patents
Analgesic and sedative in emergence recovery from anesthesiaInfo
- Publication number
- JPS62111925A JPS62111925A JP24902385A JP24902385A JPS62111925A JP S62111925 A JPS62111925 A JP S62111925A JP 24902385 A JP24902385 A JP 24902385A JP 24902385 A JP24902385 A JP 24902385A JP S62111925 A JPS62111925 A JP S62111925A
- Authority
- JP
- Japan
- Prior art keywords
- sedative
- acetylsalicylic acid
- anesthesia
- analgesic
- recovery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
(イ)利用分野
本発明はアセチル1リチル酸の水溶性誘導体を有効成分
とする麻酔覚醒時の鎮静鎮痛剤に関する。DETAILED DESCRIPTION OF THE INVENTION (a) Field of Application The present invention relates to a sedative analgesic agent for awakening from anesthesia, which contains a water-soluble derivative of acetyl monolithylic acid as an active ingredient.
(T:1)従来技術
手術などりlからの刺激を感覚としてとらえた場合、交
感神経の興奮をきたし、血管や気管支など平滑筋の収縮
や骨格筋の反射的緊張をひきおこす。(T:1) Conventional technology When the stimulus from a surgical procedure is perceived as a sensation, it excites the sympathetic nerves, causing contraction of smooth muscles such as blood vessels and bronchi, and reflex tension of skeletal muscles.
その結末、麻酔覚醒時には急激な血圧の一ヒ昇、脈拍の
増加、呼吸の抑制などをもたらす。As a result, upon awakening from anesthesia, a sudden rise in blood pressure, an increase in pulse rate, and suppression of breathing occur.
こうして術後疼痛は、外科的因子の他に手術に対する抽
々な不安や緊張が重なってひきおこされ、麻酔覚醒時か
ら数時間にわたり生じる。In this way, postoperative pain is caused by a combination of surgical factors and general anxiety and tension about the surgery, and occurs for several hours after awakening from anesthesia.
特に全身麻酔として繁用されるGOE[エンフルレン+
笑気(亜酸化窒素)十酸素]麻酔、GOF(ハロセン子
笑気+酸素)麻酔の場合に問題となることが注目されて
いる。GOE [enflurane +
It has been noticed that this can be a problem in the case of laughing gas (nitrous oxide) decaxygen anesthesia and GOF (halogenated laughing gas + oxygen) anesthesia.
(ハ)本発明が解決しようとする問題点このような術後
疼痛を抑えるためにペンクシシン、インドメタシン、イ
ブプロフェンのような鎮静剤が用いられているが、必ず
しも満足すべき結果は得られていない。(c) Problems to be Solved by the Invention Although sedatives such as penxicin, indomethacin, and ibuprofen have been used to suppress such postoperative pain, satisfactory results have not always been obtained.
そこで本発明者らは、この術後疼痛を抑えるべく各種薬
剤について検討した結果、アセチル1リチル酸の水溶性
誘導体を患者の疼痛発現以前に適宜用いることにより、
術後疼痛の鎮痛、および覚醒時興奮の鎮静に効果がある
ことを見出して本発明を完成した。Therefore, the present inventors investigated various drugs to suppress this postoperative pain, and found that by appropriately using a water-soluble derivative of acetyl monolithylic acid before the onset of pain in patients,
The present invention was completed after discovering that it is effective in analgesing postoperative pain and calming excitement during awakening.
(ニ)問題点を解決するだめの手段
本発明で用いられるアセチルサリチル酸の水溶性誘導体
としては広く公知のものが用いられるが、好適には、ア
セチルサリチル酸とアルカリ土類金属(NaSKなど)
、アルカリ金属(Ca、、Mgなど)塩基性物質とで塩
を形成したものが用いられる。(d) Means for solving the problem Widely known water-soluble derivatives of acetylsalicylic acid are used in the present invention, but preferably acetylsalicylic acid and an alkaline earth metal (such as NaSK) are used.
, alkali metals (Ca, Mg, etc.) formed into salts with basic substances are used.
この中で、塩基性物質として、塩基性アミノ酸が特に好
ましい。このようなものとして、例えばリジン、アルギ
ニン、特に、Dl、、−リジンが挙げられる。Among these, basic amino acids are particularly preferred as the basic substance. These include, for example, lysine, arginine, in particular Dl,,-lysine.
本発明のアセチルサリチル酸の水溶性誘導体として、特
に好適には、アセチルサリチル酸−L) L〜リジン塩
が用いられる。なお、このアセチルサリチル酸−1)
L −1)ジン塩の調製法としては特開昭56−101
10号明細書などに記載されている方法を用いればよい
。As the water-soluble derivative of acetylsalicylic acid of the present invention, acetylsalicylic acid L) L~lysine salt is particularly preferably used. Furthermore, this acetylsalicylic acid-1)
L-1) The method for preparing gin salt is described in JP-A-56-101.
The method described in Specification No. 10 etc. may be used.
本発明の製剤としては、たとえば、注射剤が好適であり
、アセチルサリチル酸の水溶性誘導体を注射用蒸留水、
生理食塩液、その他の水性溶媒等で用時溶解することで
調製される。For example, the preparation of the present invention is preferably an injection, in which a water-soluble derivative of acetylsalicylic acid is mixed with distilled water for injection,
It is prepared by dissolving it in physiological saline or other aqueous solvents before use.
もぢろん、通常の注射剤に配合されろ添加剤、例えば、
緩衝剤、溶解補助剤、等張侘剤、防腐剤等を配合するこ
とが好ましい。Of course, there are additives that are added to regular injections, such as:
It is preferable to include a buffer, a solubilizing agent, an isotonic stabilizer, a preservative, and the like.
本発明の製剤におけろアセチルサリチル酸の水溶性誘導
体は用時に通常、5〜20w/v%、好ましくは、IO
W/V% 程度の水溶液に調製される。In the formulation of the present invention, the water-soluble derivative of acetylsalicylic acid is usually 5 to 20 w/v%, preferably IO
It is prepared into an aqueous solution of about W/V%.
本発明の製剤は、場合によってはアセチルサリチル酸の
水溶性誘導体に加えて他の薬効成分を配合してもよい。The preparation of the present invention may optionally contain other medicinal ingredients in addition to the water-soluble derivative of acetylsalicylic acid.
本発明製剤の製造方法は公知の方法に準じればよい。The preparation of the present invention may be produced in accordance with known methods.
本発明の製剤は、術後疼痛の鎮静および覚醒時8奮の鎮
静等に適用される。The preparation of the present invention is applicable to sedating postoperative pain and sedating symptoms during awakening.
本発明の製剤は、通常、静脈内に投り、されろ。The formulations of the invention are typically administered intravenously.
その投与量としては、麻酔の程度、患者の年齢、体重、
性差、状態などに応じて適宜選択すればよいが、通常1
回当たり、”アセチルサリチル酸として100−100
0mg用いられる。The dosage depends on the degree of anesthesia, age and weight of the patient,
It may be selected appropriately depending on gender, condition, etc., but usually 1.
100-100% as acetylsalicylic acid per serving
0 mg is used.
投与時期としては、麻酔導入時から覚醒前の間であれば
よ(、好適には覚醒前10〜60分の間に行なわれる。The administration may be performed from the time of induction of anesthesia to before awakening (preferably from 10 to 60 minutes before awakening).
(ホ)本発明の効果
本発明の製剤を用いると、覚醒時の意識に作用すること
なく患者の安静度も大変によい。(e) Effects of the present invention When the preparation of the present invention is used, the patient's level of rest is very good without affecting consciousness during awakening.
従って、手術直後の患者の痛みを取るのに大変有効であ
ることが判明した。Therefore, it was found to be very effective in alleviating pain in patients immediately after surgery.
また、注射剤であるので、投与が極めて容易に行なわれ
、内服剤で知られているような胃腸障害を惹起すること
もない。Furthermore, since it is an injection, it is extremely easy to administer and does not cause gastrointestinal disorders as is known with oral preparations.
このように本発明の製剤は、術後疼痛の鎮痛、鎮静剤と
して臨床−L有用である。Thus, the preparation of the present invention is clinically useful as an analgesic and sedative for post-operative pain.
(へ)臨床例
本発明の詳細な説明するために臨床例を挙げるが、本発
明はこれらによって何ら限定されない。(f) Clinical Examples Although clinical examples are given to explain the present invention in detail, the present invention is not limited by these in any way.
臨床例
整形外科の手術を行なう患者(男性、年齢26オ、体重
65kg)に術前60分に前投薬としてアストロピン0
.5mg、ヒドロキシジン50mgを筋注した。 麻酔
導入時には、チオペンクール200mg、塩化スキサメ
1−ニウム50mgを静注した後、GOE (エンフル
ラン+笑気十酸素)[笑気4β/分、酸素2β/分、エ
ンフルラン濃度1−2%を維持]により吸入麻酔を開始
し、手術は予定通り施行した。麻酔終了30分前にヴエ
ノピリン(アセチルサリチル酸−D L−リジン塩(株
)ミドリ十字製)■バイアル(アセチルサリチル酸とし
て498mg>を静注した。患者の反応は正常で覚醒時
痛みを訴えることもなく、安静度も良好であった。その
後30分毎に患者を問診したが、特に変化はなかった。Clinical example A patient (male, age 26, weight 65 kg) undergoing orthopedic surgery was given 0 astropine as a premedication 60 minutes before surgery.
.. 5 mg of hydroxyzine and 50 mg of hydroxyzine were intramuscularly injected. At the time of induction of anesthesia, after intravenously injecting 200 mg of thiopencour and 50 mg of suxasame 1-nium chloride, GOE (enflurane + laughing gas decaoxygen) [laughing gas 4β/min, oxygen 2β/min, maintaining enflurane concentration 1-2%] was used. Inhalation anesthesia was started, and the surgery was performed as scheduled. Thirty minutes before the end of anesthesia, a vial of venopyrine (acetylsalicylic acid - D L-lysine salt manufactured by Midori Juji Co., Ltd.) (498 mg as acetylsalicylic acid) was injected intravenously.The patient's reactions were normal and he did not complain of pain upon awakening. The patient's rest level was also good.After that, the patient was interviewed every 30 minutes, but there was no particular change.
また、重篤な副作用も観察されなかった。Also, no serious side effects were observed.
製剤例
アセチルサリチル酸 900mg
−DL−リジン塩
着色防止剤 アミノ酢酸 100mg安定剤
塩化力ルンウム 50mg(無水物)
計 1050mg
有効成分のアセチルサリチル酸−D L −IJジンj
fffi90[]mgは、アセチルサリチル酸498m
gとD L、−リジン402mgとからなる塩である。Formulation example Acetylsalicylic acid 900mg -DL-Lysine salt Color inhibitor Aminoacetic acid 100mg Stabilizer Chloride 50mg (anhydride) Total 1050mg Active ingredient Acetylsalicylic acid -DL -IJjinj
fffi90[]mg is 498m acetylsalicylic acid
g and 402 mg of DL, -lysine.
使用時は注射用蒸留水I QmI2に溶解して静脈内注
射剤とした。When used, it was dissolved in distilled water for injection IQmI2 to prepare an intravenous injection.
特許出願人 株式会社 ミドリ十字手続ネIn 1
F’tan
昭和60年12月26日
特酌庁長官 殿
1、 事イ!1の表示
昭和6(用特IF願第2/19023号2、 発明の名
称
麻酔覚醒1[、′Iの鎮痛鎮静剤
3、 補正を4る省
事1′1との関係: 特ム1出願人
名称: 株式会ネ1ミドリ十字
6、 補正により増加する発明の数: 07、 補正の
対象: 明細用の「発明の詳細な説明」の欄8、 補正
の内容: 明IBIF3第6頁第10〜11行目、[患
者の反応は正常で覚醒時1を1覚醒時患省の反応はi「
常r]ど補正する。Patent applicant: Midori Juji Procedures In 1
F'tan December 26, 1985 Director-General of the Special Consideration Agency Tono 1, Incident! 1 Indication of Showa 6 (Special IF Application No. 2/190232, Title of invention Anesthesia Awakening 1 [, 'I Analgesic Sedatives 3, Amendment 4 Ministry of Affairs 1'1 Relationship with: Patent 1 Applicant Name: Co., Ltd. Ne1 Midorijuji 6 Number of inventions increased by the amendment: 07 Target of the amendment: Column 8 of “Detailed Description of the Invention” for specifications Contents of the amendment: Mei IBIF 3, page 6, No. 10- Line 11, [The patient's reaction is normal and 1 when awake. 1 When the patient is awake, the patient's reaction is i"
Always correct.
Claims (2)
60分に投与される麻酔覚醒時の鎮痛鎮静剤がアセチル
サリチル酸の水溶性誘導体であることを特徴とする麻酔
覚醒時の鎮痛鎮静剤。(1) During surgery under general anesthesia, 10 to 10 minutes before awakening
An analgesic and sedative for awakening from anesthesia, characterized in that the analgesic and sedative for awakening from anesthesia, which is administered at 60 minutes, is a water-soluble derivative of acetylsalicylic acid.
リチル酸−DL−リジン塩であることを特徴とする麻酔
覚醒時の鎮痛鎮静剤。(2) An analgesic and sedative for awakening from anesthesia, characterized in that the water-soluble derivative of acetylsalicylic acid is acetylsalicylic acid-DL-lysine salt.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP24902385A JPS62111925A (en) | 1985-11-08 | 1985-11-08 | Analgesic and sedative in emergence recovery from anesthesia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP24902385A JPS62111925A (en) | 1985-11-08 | 1985-11-08 | Analgesic and sedative in emergence recovery from anesthesia |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS62111925A true JPS62111925A (en) | 1987-05-22 |
Family
ID=17186857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP24902385A Pending JPS62111925A (en) | 1985-11-08 | 1985-11-08 | Analgesic and sedative in emergence recovery from anesthesia |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62111925A (en) |
-
1985
- 1985-11-08 JP JP24902385A patent/JPS62111925A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vickers | Gammahydroxybutyric acid | |
ES2395462T3 (en) | Selective norepinephrine-serotonin reuptake inhibitors for the treatment of fibromyalgia syndrome, chronic fatigue syndrome and pain | |
JP5757677B2 (en) | Prevention and / or treatment of portal hypertension | |
RU2244558C2 (en) | Anesthetic composition comprising nmda-antagonist and alpha-2-adrenergic agonist | |
BR112020023452A2 (en) | gip / glp1 agonist compositions | |
Klamt et al. | Postoperative analgesic effect of intrathecal neostigmine and its influence on spinal anaesthesia | |
JP2003529541A6 (en) | Anesthetic preparation containing NMDA antagonist and α2 adrenergic agonist | |
JP2009508590A (en) | Anesthesia induction and drug maintenance | |
PHILLIPS et al. | Intravenous lidocaine as an adjunct to general anesthesia: a clinical evaluation | |
JPS62298530A (en) | Pharmaceutical composition for suppository | |
JPS63135330A (en) | Antianxiety | |
JP4939751B2 (en) | Use of xenon to control neuropathy related to cardiopulmonary bypass | |
CA2165446C (en) | Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade | |
JPS62111925A (en) | Analgesic and sedative in emergence recovery from anesthesia | |
JPH06172187A (en) | Medicine for muscular dystrophy | |
Dodds | Anaesthetic drugs in the elderly | |
EP3236956A1 (en) | Combination of remifentanil and propofol | |
Hiatt | Local anesthesia: history; potential toxicity; clinical investigation of mepivacaine | |
APPLETON et al. | A Neuroinhibitory Substance: Gamma Hydroxybutyric Acid preliminary report of first clinical trial in Britain | |
JP4358535B2 (en) | Stable aqueous pharmaceutical composition containing acetaminophen | |
JP2003171266A (en) | Antipyretic preparation containing xylitol | |
JPS632926A (en) | Stable injectable antiemetic composition | |
Adams et al. | The clinical effectiveness of a disposable aspirating syringe | |
JPH01501708A (en) | Nasal administration of amino acids | |
JPS6345371B2 (en) |